S&P 500   3,117.19 (-0.10%)
DOW   27,862.25 (-0.26%)
QQQ   203.15 (-0.11%)
CGC   17.18 (+12.14%)
BABA   182.97 (-1.23%)
GE   11.44 (-0.52%)
T   36.89 (-2.95%)
F   8.81 (-1.12%)
BAC   32.74 (-0.61%)
DIS   147.83 (-0.37%)
S&P 500   3,117.19 (-0.10%)
DOW   27,862.25 (-0.26%)
QQQ   203.15 (-0.11%)
CGC   17.18 (+12.14%)
BABA   182.97 (-1.23%)
GE   11.44 (-0.52%)
T   36.89 (-2.95%)
F   8.81 (-1.12%)
BAC   32.74 (-0.61%)
DIS   147.83 (-0.37%)
S&P 500   3,117.19 (-0.10%)
DOW   27,862.25 (-0.26%)
QQQ   203.15 (-0.11%)
CGC   17.18 (+12.14%)
BABA   182.97 (-1.23%)
GE   11.44 (-0.52%)
T   36.89 (-2.95%)
F   8.81 (-1.12%)
BAC   32.74 (-0.61%)
DIS   147.83 (-0.37%)
S&P 500   3,117.19 (-0.10%)
DOW   27,862.25 (-0.26%)
QQQ   203.15 (-0.11%)
CGC   17.18 (+12.14%)
BABA   182.97 (-1.23%)
GE   11.44 (-0.52%)
T   36.89 (-2.95%)
F   8.81 (-1.12%)
BAC   32.74 (-0.61%)
DIS   147.83 (-0.37%)
Log in

Neurocrine Biosciences Stock Price, Forecast & Analysis (NASDAQ:NBIX)

$113.14
+0.41 (+0.36 %)
(As of 11/20/2019 11:19 AM ET)
Today's Range
$112.49
Now: $113.14
$114.43
50-Day Range
$86.89
MA: $98.83
$114.95
52-Week Range
$64.72
Now: $113.14
$116.06
Volume8,771 shs
Average Volume767,257 shs
Market Capitalization$10.42 billion
P/E Ratio514.27
Dividend YieldN/A
Beta1.2
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$451.24 million
Cash Flow$0.50 per share
Book Value$5.30 per share

Profitability

Net Income$21.11 million

Miscellaneous

Employees585
Market Cap$10.42 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Monday, November, 4th. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.63 by $0.07. The business earned $222.09 million during the quarter, compared to analysts' expectations of $211.31 million. Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. Neurocrine Biosciences's revenue for the quarter was up 46.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.52 EPS. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

18 equities research analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their forecasts range from $84.00 to $122.00. On average, they expect Neurocrine Biosciences' share price to reach $106.47 in the next twelve months. This suggests that the stock has a possible downside of 5.9%. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Has Neurocrine Biosciences been receiving favorable news coverage?

Headlines about NBIX stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurocrine Biosciences earned a news impact score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the near term. View News Stories for Neurocrine Biosciences.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a decrease in short interest during the month of October. As of October 15th, there was short interest totalling 3,340,000 shares, a decrease of 5.4% from the September 15th total of 3,530,000 shares. Based on an average daily volume of 691,200 shares, the short-interest ratio is presently 4.8 days. Currently, 3.7% of the company's shares are short sold. View Neurocrine Biosciences' Current Options Chain.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Gilead Sciences (GILD), Netflix (NFLX), Celgene (CELG), Twilio (TWLO), Illumina (ILMN) and Exelixis (EXEL).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.79%), GW&K Investment Management LLC (0.32%), Handelsbanken Fonder AB (0.22%), California Public Employees Retirement System (0.17%), Rhenman & Partners Asset Management AB (0.16%) and Massachusetts Financial Services Co. MA (0.14%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Rhenman & Partners Asset Management AB, Mission Wealth Management LP, Oakbrook Investments LLC, Daiwa Securities Group Inc., Fox Run Management L.L.C., SG Americas Securities LLC and Fisher Asset Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Richard F Pops. View Insider Buying and Selling for Neurocrine Biosciences.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, GW&K Investment Management LLC, California Public Employees Retirement System, Handelsbanken Fonder AB, Assenagon Asset Management S.A., EFG Asset Management Americas Corp., Lisanti Capital Growth LLC and Cookson Peirce & Co. Inc.. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $113.14.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $10.42 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  802 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  1,063
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel